Acute decompensated heart failure (ADHF) is the most common cause of cardiovascular hospitalization. The presentation is characterized by different clinical profiles due to various underlying causes, volume balance and tissue perfusion status. Currently, a variety of pharmacological therapies, including diuretics, betablockers, ACE-inhibitors, angiotensin receptor blockers and digoxin, are usually prescribed in order to treat chronic heart failure (HF) syndromes caused by left ventricular systolic dysfunction. Despite the large number ofHF patients with frequent hospitalizations for decompensation, only a fewstudies have evaluated the management of oral chronic therapies in the clinical setting of ADHF. This article summarizes the information derived from the few published trials on this subject and a therapeutic approach is suggested with respect to the continuation, dose modification or suspension of oral medications. © 2014 Elsevier Ireland Ltd. All rights reserved.
Management of oral chronic pharmacotherapy in patients hospitalized for acute decompensated heart failure / Piepoli, Massimo; Binno, Simone Maurizio; Quinto Villani, Giovanni; Cabassi, Aderville. - In: INTERNATIONAL JOURNAL OF CARDIOLOGY. - ISSN 0167-5273. - 176:2(2014), pp. 321-326. [10.1016/j.ijcard.2014.07.085]
Management of oral chronic pharmacotherapy in patients hospitalized for acute decompensated heart failure
Simone Binno;Aderville Cabassi
2014-01-01
Abstract
Acute decompensated heart failure (ADHF) is the most common cause of cardiovascular hospitalization. The presentation is characterized by different clinical profiles due to various underlying causes, volume balance and tissue perfusion status. Currently, a variety of pharmacological therapies, including diuretics, betablockers, ACE-inhibitors, angiotensin receptor blockers and digoxin, are usually prescribed in order to treat chronic heart failure (HF) syndromes caused by left ventricular systolic dysfunction. Despite the large number ofHF patients with frequent hospitalizations for decompensation, only a fewstudies have evaluated the management of oral chronic therapies in the clinical setting of ADHF. This article summarizes the information derived from the few published trials on this subject and a therapeutic approach is suggested with respect to the continuation, dose modification or suspension of oral medications. © 2014 Elsevier Ireland Ltd. All rights reserved.I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
